Revenio Group has signed an agreement to acquire the entire share capital of France-based LT International SAS, the parent company of the Visionix International group, in a transaction valued at €290 million ($342 million). 

The acquisition brings together two players in ophthalmic diagnostics and optical technologies, positioning the combined entity as a turnkey solutions provider across optometry, optical retail, and ophthalmology, according to Revenio. The acquisition broadens Revenio’s product portfolio. Its current iCare-branded offerings—including tonometers, fundus imaging devices, and perimeters—will be complemented by Visionix’s extensive range of diagnostic, refraction, OCT, and lens finishing solutions.

Based on 2025 figures, the combined group is expected to generate more than €250 million in annual sales, €48 million in adjusted EBITDA, and employ over 800 people worldwide.

Key Highlights of the Transaction

The agreement is expected to deliver multiple strategic and financial benefits:

  • Expanded Market Reach: Revenio’s total addressable market is expected to increase approximately 2.5 times, reaching around $2.5 billion
  • Entry into High-Growth Segments: The acquisition provides immediate access to the optical coherence tomography (OCT) market, valued at approximately $700 million and among the fastest-growing segments in eye care diagnostics
  • Synergy Potential: The companies are targeting more than €20 million in EBITDA uplift through synergies and joint value creation initiatives by the end of 2029
  • Improved Commercial Capabilities: Enhanced route-to-market through expanded direct sales presence and cross-selling opportunities across customer segments
  • Scale Benefits: Cost efficiencies are expected through integration of operations, IT systems, and supply chains

The total consideration payable to Visionix shareholders is €250 million, including €55.7 million in newly issued Revenio shares. This equity component ensures that Visionix’s existing owners remain invested in the combined company.

As part of the agreement, Revenio’s board has proposed adding three new members: Charles Vilgrain (Caravelle Capital), Dr. Marc Abitbol (Visionix CEO), and Nicklas Hansen (William Demant Invest). 

The transaction is expected to close by the end of the second quarter of 2026, subject to shareholder approvals and customary conditions.